Here, we characterize a novel disease mechanism for congenital myasthenic syndrome in which a mutation in a nuclear envelope protein, LAP1, gives rise to impaired neuromuscular transmission which has not been seen in other associated nuclear envelopathies, but highlights a potential novel pathway for the disruption of synaptic transmission. Here, TOR1AIP1 is linked to Congenital myasthenic syndromes.